A huge study of Pfizer's blockbuster vaccine against pneumonia and other bacterial infections in adults 65 and older found it protected most of them against dangerous infections in the bloodstream and other sterile body areas.
That age group is particularly vulnerable, because normal weakening of the immune system as people age makes them more likely to get life-threatening pneumonia and other infections caused by the bacteria.
Read more